Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OXEYE trial of suprachoroidal OXU-001 versus intravitreal Ozurdex in diabetic macular edema
2023-503496-17-00Phase 2Completed
- Sponsor
- Oxular Limited
- Start
- Aug 2023
- Modality
- Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 4
01
Overview
Phase 2, randomised, single-blind trial of OXU-001 and ozurdex in diabetic macular edema (DME) (3 arms), sponsored by Oxular Limited. Started Aug 2023; status: completed.
02
Drugs
OXU-001ozurdex
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2023-503496-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503496-17-00.